<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69866</article-id><article-id pub-id-type="doi">10.7554/eLife.69866</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>Convalescent plasma use in the United States was inversely correlated with COVID-19 mortality</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-45406"><name><surname>Casadevall</surname><given-names>Arturo</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9402-9167</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236514"><name><surname>Dragotakes</surname><given-names>Quigly</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236515"><name><surname>Johnson</surname><given-names>Patrick W</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236516"><name><surname>Senefeld</surname><given-names>Jonathon W</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236523"><name><surname>Klassen</surname><given-names>Stephen A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236522"><name><surname>Wright</surname><given-names>R Scott</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236519"><name><surname>Joyner</surname><given-names>Michael J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236520"><name><surname>Paneth</surname><given-names>Nigel</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236521"><name><surname>Carter</surname><given-names>Rickey E</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Molecular Microbiology and Immunology</institution>, <institution>Johns Hopkins Bloomberg School of Public Health</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution>Johns Hopkins School of Public Health</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution>Mayo Clinic</institution>, <addr-line><named-content content-type="city">Jacksonviille</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution>Mayo Clinic</institution>, <addr-line><named-content content-type="city">Rochester</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution>Michigan State University</institution>, <addr-line><named-content content-type="city">East Lansing</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution>Mayo Clinic</institution>, <addr-line><named-content content-type="city">Jacksonville</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-190571"><name><surname>Iqbal</surname><given-names>Jameel</given-names></name><role>Reviewing editor</role><aff><institution>James J Peters Veterans Affairs Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>acasade1@jhu.edu</email> (AC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>04</day><month>06</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e69866</elocation-id><history><date date-type="received"><day>28</day><month>04</month><year>2021</year></date><date date-type="accepted"><day>03</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Casadevall et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Casadevall et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-69866-v1.pdf"/><abstract><p><bold>Background</bold>. The US Food and Drug Administration authorized Convalescent Plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for the US.</p><p><bold>Methods.</bold> We tracked the number of CCP units dispensed to hospitals by blood banking organizations and correlated that usage with hospital admission and mortality data.</p><p><bold>Results</bold>. CCP usage per admission peaked in Fall 2020, with more than 40% of inpatients estimated to have received CCP between late September and early November 2020. However, after randomized controlled trials failed to show a reduction in mortality, CCP usage per admission declined steadily to a nadir of less than 10% in March 2021. We found a strong inverse correlation (r = -0.52, P = 0.002) between CCP usage per hospital admission and deaths occurring two weeks after admission, and this finding was robust to examination of deaths taking place one, two or three weeks after admission. Changes in the number of hospital admissions, SARS-CoV-2 variants, and age of patients could not explain these findings. The retreat from CCP usage might have resulted in as many as 29,000 excess deaths from mid-November 2020 to February 2021.</p><p><bold>Conclusions</bold>. A strong inverse correlation between CCP use and mortality per admission in the USA provides population level evidence consistent with the notion that CCP reduces mortality in COVID-19 and suggests that the recent decline in usage could have resulted in excess deaths.</p><p><bold>Funding. </bold>There was no specific funding for this study. AC was supported in part by RO1 HL059842 and R01 AI1520789; MJJ was supported in part by 5R35HL139854. This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>AI1520789</award-id><principal-award-recipient><name><surname>Casadevall</surname><given-names>Arturo</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012399</institution-id><institution>Biomedical Advanced Research and Development Authority</institution></institution-wrap></funding-source><award-id>75A50120C00096</award-id><principal-award-recipient><name><surname>Joyner</surname><given-names>Michael J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files</p></sec><supplementary-material><ext-link xlink:href="elife-69866-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>